FH
FHTX
Foghorn Therapeutics Inc.
$4.02
+0.50%
$234.9M
No data for this timeframe.
Vol
Market Cap$234.9M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders8 funds
Inst. Value$43.0M
Inst. Activity5 buys / 0 sells
SEC Reports2
Press Releases1
Recent Activity
May 11, 2026
earnings_calendar
FHTX Q1 2026 Earnings Before Market Open — 2026-05-11
May 7, 2026
SEC
Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss of $19.9M (vs $18.8
8-K — Impact 3/10
Apr 21, 2026
SEC
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing promising results across its pipeline, includin
8-K — Impact 7/10
Apr 10, 2026
Insider
GOTTSCHALK ADRIAN sold 59,208 shares
Chief Executive Officer @ $0.00 ($0.00)
Apr 9, 2026
Insider
GOTTSCHALK ADRIAN sold 47,497 shares
Chief Executive Officer @ $0.00 ($0.00)
Feb 23, 2026
Insider
Maynard Ryan D sold 400,000 shares
Chief Financial Officer @ $5.75 ($2.3M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
297,736 shares ($1.6M)
Inst.
MORGAN STANLEY — ADD
121,727 shares ($657.3K)
Price Targets
$11.44
+184.7% upside
Strong Buy
Current $4.02
Low $9.00
Median $12.00
High $14.00
9 analysts
$9.00
$14.00
Analyst Ratings
7Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 12, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 17, 2026 | Jefferies | MAINTAIN | Buy → Buy |
| Dec 18, 2025 | BTIG | INITIATE | Buy |
| Dec 4, 2025 | Stifel | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 ▲ +28.7% | $-0.32 — $-0.14 | 17% YoY | 7 |
| Next Q | $-0.24 ▲ +29.4% | $-0.33 — $-0.15 | 4% YoY | 7 |
| Current FY | $-0.99 ▲ +12.5% | $-1.34 — $-0.70 | 18% YoY | 7 |
| Next FY | $-0.93 ▼ -1.9% | $-1.40 — $-0.63 | 6% YoY | 7 |
Latest Reports
NEUTRAL
8-K
3/10
Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss of $19.9M (vs $18.8
May 7, 2026
BULLISH
8-K
7/10
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing promising results across its pipeline, includin
Apr 21, 2026
BULLISH
Press
7/10
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing complete and durable tumor regression with its
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $29.1M | — |
| VANGUARD GROUP INC | $10.4M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.6M | DOUBLED |
| MORGAN STANLEY | $657.3K | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $444.8K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 10, 2026 | GOTTSCHALK ADRIAN | G | $0.00 |
| Apr 9, 2026 | GOTTSCHALK ADRIAN | G | $0.00 |
| Feb 23, 2026 | Maynard Ryan | A | $2.3M |
| Feb 5, 2026 | GOTTSCHALK ADRIAN | A | $5.6M |
| Jan 30, 2026 | Costa Carlos | A | $1.3M |
8 institutional holders with $43.0M total value (7,956,846 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, RENAISSANCE. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 5,396,814 | $29.1M | 67.8% | — |
| 2 | VANGUARD GROUP INC | 1,928,992 | $10.4M | 24.2% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 297,736 | $1.6M | 3.7% | DOUBLED +151.8% |
| 4 | MORGAN STANLEY | 121,727 | $657.3K | 1.5% | ADD +91.2% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 82,363 | $444.8K | 1.0% | ADD +30.0% |
| 6 | BANK OF AMERICA CORP /DE/ | 73,859 | $398.8K | 0.9% | DOUBLED +145.7% |
| 7 | WELLS FARGO & COMPANY/MN | 38,755 | $209.3K | 0.5% | ADD +58.4% |
| 8 | TWO SIGMA INVESTMENTS, LP | 16,600 | $89.6K | 0.2% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 118,236 | 297,736 | +151.8% | $1.6M | 2025-Q4 |
| MORGAN STANLEY | ADD | 63,676 | 121,727 | +91.2% | $657.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 30,063 | 73,859 | +145.7% | $398.8K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 24,474 | 38,755 | +58.4% | $209.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 16,600 | — | $89.6K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 62,636 | 118,236 | +88.8% | $578.2K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 75,495 | 98,177 | +30.0% | $461.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 23,835 | 31,297 | +31.3% | $147.1K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 16,136 | 21,043 | +30.4% | $98.9K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 97,545 | 69,471 | -28.8% | $253.6K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 25,236 | 47,736 | +89.2% | $225.3K | 2024-Q4 |
| UBS Group AG | DOUBLED | 11,930 | 37,495 | +214.3% | $177.0K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 11,883 | 15,841 | +33.3% | $74.8K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 92,204 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | ADD | 65,098 | 108,201 | +66.2% | $1.0M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 75,495 | — | $702.9K | 2024-Q3 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 10, 2026 | GOTTSCHALK ADRIAN | Chief Executive Officer | G | 59,208 | $0.00 | $0.00 |
| Apr 9, 2026 | GOTTSCHALK ADRIAN | Chief Executive Officer | G | 47,497 | $0.00 | $0.00 |
| Feb 23, 2026 | Maynard Ryan D | Chief Financial Officer | A | 400,000 | $5.75 | $2.3M |
| Feb 5, 2026 | GOTTSCHALK ADRIAN | Chief Executive Officer | A | 1,075,000 | $5.23 | $5.6M |
| Jan 30, 2026 | Costa Carlos | Chief People Officer | A | 230,000 | $5.71 | $1.3M |
| Jan 30, 2026 | Bellon Steven F. | Chief Scientific Officer | A | 300,000 | $5.71 | $1.7M |
| Jan 30, 2026 | Cardama Alfonso Quintas | Chief Medical Officer | A | 300,000 | $5.71 | $1.7M |
| Jan 30, 2026 | Rivkin Anna | Chief Business Officer | A | 165,000 | $5.71 | $942.1K |
| Jan 30, 2026 | LaCascia Michael | Chief Legal Officer | A | 295,000 | $5.71 | $1.7M |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 7 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.44 mean target
+184.7% upside
Strong Buy (1.10)
$9.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $4.02 |
| Target Low | $9.00 |
| Target Mean | $11.44 |
| Target Median | $12.00 |
| Target High | $14.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.10) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.32 | $-0.14 | 16.8% | +28.7% | 1↑ 0↓ | $0.0B | 5.0% | 7 |
| Next Q 2026-09-30 |
$-0.24 | $-0.33 | $-0.15 | 4.0% | +29.4% | 1↑ 0↓ | $0.0B | -0.0% | 7 |
| Current FY 2026-12-31 |
$-0.99 | $-1.34 | $-0.70 | 17.9% | +12.5% | — | $0.0B | -16.4% | 7 |
| Next FY 2027-12-31 |
$-0.93 | $-1.40 | $-0.63 | 6.2% | -1.9% | 1↑ 2↓ | $0.0B | 44.8% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.233 | |
| 7d ago | $-0.313 | +0.080 |
| 30d ago | $-0.327 | +0.094 |
| 60d ago | $-0.310 | +0.077 |
| 90d ago | $-0.302 | +0.070 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 12, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 17, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | BTIG | INITIATE | — | Buy |
| Dec 4, 2025 | Stifel | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
earnings_calendar
FHTX Q1 2026 Earnings Before Market Open — 2026-05-11
May 7, 2026
earnings
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
<p align="center"><em>- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates
Apr 21, 2026
fda
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
<p align="center">- <em>Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with
Apr 9, 2026
routine
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
<p align="center"><em>New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-P
Mar 11, 2026
earnings
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
<p align="center"><em>FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-sm
Mar 5, 2026
earnings_calendar
FHTX Q4 2025 Earnings After Market Close — 2026-03-05
Mar 4, 2026
earnings_calendar
FHTX Q4 2025 Earnings After Market Close — 2026-03-04